3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Leukemia
1
Interventions
Cytarabine
16
Methotrexate
13
Specimen Handling
12
venetoclax
11
Cyclophosphamide
11
fludarabine
8
Whole-Body Irradiation
8
Biopsy
8
merphos
7
fludarabine phosphate
7
calaspargase pegol
7
Vincristine
7
Hydrocortisone
7
blinatumomab
6
Granulocyte Colony-Stimulating Factor
6
Dexamethasone
6
revumenib
5
Mycophenolic Acid
5
Leucovorin
5
Filgrastim
5
Daunorubicin
5
Calcium Dobesilate
5
Asparaginase
5
prednylidene
4
dexamethasone acetate
4
dexamethasone 21-phosphate
4
deltacortene
4
Thioguanine
4
Tacrolimus
4
Stem Cell Transplantation
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia, Biphenotypic, Acute
×
Cobicistat
×
90 days
×
Clear all
NCT04065399
2026-03-18
AUGMENT-101
Syndax Pharmaceuticals
Phase 1/2
Recruiting
447 enrolled
2 FDA